US 11,865,206 B2
Stable ready-to-use carmustine pharmaceutical composition
Sougata Pramanick, Bhosari (IN); Aasiya Aslam Burhan, Bhosari (IN); Mukund Keshav Gurjar, Bhosari (IN); Hiren Pravinbhai Patel, Bhosari (IN); and Deepak Pragjibhai Gondaliya, Bhosari (IN)
Assigned to EMCURE PHARMACEUTICALS LTD, Pune (IN)
Filed by EMCURE PHARMACEUTICALS LTD., Pune (IN)
Filed on Dec. 28, 2022, as Appl. No. 18/089,652.
Application 18/089,652 is a continuation of application No. 17/268,022, abandoned, previously published as PCT/IB2019/057404, filed on Sep. 3, 2019.
Claims priority of application No. 201821033221 (IN), filed on Sep. 5, 2018.
Prior Publication US 2023/0135144 A1, May 4, 2023
Int. Cl. C07D 471/04 (2006.01); A01N 43/90 (2006.01); A61K 9/00 (2006.01); A61K 31/175 (2006.01); A61K 47/26 (2006.01)
CPC A61K 9/0029 (2013.01) [A61K 31/175 (2013.01); A61K 47/26 (2013.01)] 10 Claims
 
1. A method of administering carmustine to a patient consisting of:
(i) providing a carmustine solution consisting of: (a) about 100 mg/mL to about 500 mg/mL of carmustine; and (b) a super refined polysorbate with a peroxide value below 10 meq O2/kg to a person administering carmustine to the patient wherein the carmustine solution has not been reconstituted from a lyophilizate and the carmustine solution is provided in a sealed container that is free of polyvinyl chloride and free of di-2-ethylhexylphthalate;
(ii) adding the carmustine solution of step (i) directly to 500 ml of a 0.9% sodium chloride injection solution or 500 ml of a 5% dextrose injection solution to form an administrable solution without any prior dissolution or prior dilution of the carmustine solution; and
(iii) parenterally administering the administrable solution of step (ii) to the patient.